Jacobs to support construction of $1.2bn biotech manufacturing plant

Engineering consultant Jacobs has won a deal with Fujifilm Diosynth Biotechnologies to support the delivery of a $1.2 billion expansion of a biotechnology facility in Holly Springs, North Carolina, USA.

Two people wearing hard hats and yellow Jacobs-branded hi-vis vests in front of a green Fujifilm sign Image courtesy of Jacobs

Jacobs originally supported the construction of the Holly Springs site, which broke ground in 2021. Now it is providing engineering, procurement and construction management services for the expansion, which involves construction of a large-scale cell culture contract manufacturing facility.

The facility will provide drug substance manufacturing, automated fill-finish and assembly, packaging and labelling services for global biopharmaceutical customers.

The expansion adds another eight 20,000-litre cell culture bioreactors and 400,000 square feet (37,161 square metres) of manufacturing space by 2028, in addition to the eight bioreactors for bulk drug substance already planned as part of the initial investment. That first phase of construction is planned for completion in 2025.

“Once complete, the site will be one of the largest, end-to-end cell culture contract manufacturing facilities in North America,” said Fujifilm Diosynth Biotechnologies chief operating officer and executive vice president of operations Kenneth Bilenberg.


Receive the information you need when you need it through our world-leading magazines, newsletters and daily briefings.

Sign up

Andy Brown Editor, Editorial, UK - Wadhurst Tel: +44 (0) 1892 786224 E-mail: [email protected]
Neil Gerrard Senior Editor, Editorial, UK - Wadhurst Tel: +44 (0) 7355 092 771 E-mail: [email protected]
Catrin Jones Deputy Editor, Editorial, UK – Wadhurst Tel: +44 (0) 791 2298 133 E-mail: [email protected]
Eleanor Shefford Brand Manager Tel: +44 (0) 1892 786 236 E-mail: [email protected]